A Randomised, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Inhaled Doses of Imatinib Inhalation Solution (AER-901) in Adult Healthy Volunteers
Overview
- Phase
- Phase 1
- Intervention
- AER-901 Solution for Nebulization
- Conditions
- Pulmonary Arterial Hypertension
- Sponsor
- Aerami Therapeutics
- Enrollment
- 83
- Locations
- 1
- Primary Endpoint
- Number of Participants with Treatment Emergent Adverse Events (TEAEs)
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
This is a randomised, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and PK of single and multiple inhaled doses of imatinib inhalation solution (AER-901) in healthy adult volunteers. This study consists of 3 parts and an optional fourth part.
Detailed Description
This is a randomised, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and PK of single and multiple inhaled doses of imatinib inhalation solution (AER-901) in healthy adult volunteers. This study consists of 3 parts and an optional fourth part: * Part A: double-blind, placebo-controlled, single ascending dose (SAD). * Part B: double-blind, placebo-controlled, multiple ascending dose (MAD). * Part C (optional): open-label, single-dose, crossover. The decision to proceed with Part C will be made by the Sponsor after reviewing unblinded safety and PK data from Part D of the study. * Part D: double-blind, placebo-controlled, 5 mg single dose (SD) followed by a twice daily (BID) 5 mg dose (total daily dose of 10 mg) of AER-901 in a propylene glycol formulation vs. placebo. Oversight for the study will be provided by an SRC composed of the Principal Investigator (PI), the Sponsor's Medical Monitor (MM) and an independent MM. The decision to progress from Cohort A1 to Cohort A2 will be based on safety and tolerability data and not PK data from Cohort A1. However, the decision to progress from Cohort A2 to Cohort A3 will be based on review of safety and tolerability data from Cohort A2 and PK data from Cohort A1 by the SRC. A similar sequence will follow for subsequent progression decisions by the SRC for the cohorts in Part A and Part B of the study. All parts of the study (A, B, C, and D) will include a 28-day Screening period, a Treatment period, and a Follow-up period. Parts C and D include an additional treatment period and a Washout period between the 2 treatment periods. Throughout this Study Protocol, timings for post-dose assessments for spirometry, ECG, blood and urine samples for PK analysis are stated in relation to completion of the most recent dose of IP.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Provide written consent.
- •Body weight ≥ 50 kg, and a body mass index 18.0 to 32.0, inclusive.
- •Female participants of non child bearing potential or if of child bearing potential, agrees to take effective contraceptive measures throughout the study period.
- •Male participant: has undergone bilateral vasectomy or agrees to use effective contraceptive effective contraceptive measures or abstinence, and not donate sperm throughout the study until at least 3 months after the last dose of IP.
- •Forced expiratory volume in 1 sec (FEV1)/forced vital capacity (FVC) ratio of at least 0.
- •Values for FEV1 and FVC of at least 80% of the predicted value.
- •Able to understand the nature of the study and any hazards of participation, and ability to communicate satisfactorily with the Investigator and to participate in, and comply with the requirements of, the entire study.
- •Able to successfully perform spirometry and use the inhalation device at Screening.
- •Negative result for cotinine in the urine drug screen, at Screening and on Day -1.
Exclusion Criteria
- •Clinically significant physical findings, vital signs, ECG, or laboratory values that could interfere with the objectives of the study or the safety of the subject.
- •Pregnant or lactating or planning to become pregnant (self or partner) at any time during the study, including the follow-up period.
- •Presence of acute or chronic illness or history of chronic illness.
- •Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary artery disease, or history of any psychotic mental illness.
- •Upper or lower respiratory tract infection within 4 weeks before the first dose of treatment.
- •Any medically identified respiratory disease(s) and/or condition(s), including but not limited to current asthma, chronic obstructive pulmonary disease, and diagnosed obstructive sleep apnoea syndrome.
- •Any clinically significant arrhythmia(s) at Screening ECG.
- •History of surgery or medical intervention, or planned surgery or medical intervention, that could interfere with the objectives of the study or the safety of the volunteer.
- •Currently taking any drug including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days before the first dose and throughout the study, with the exception of acetylsalicylic acid (aspirin).
- •Positive test result(s) for hepatitis C virus (HCV) antibody, hepatitis B surface antigen (HbsAg), human immunodeficiency virus (HIV) antibody, or coronavirus disease of 2019 (COVID-19).
Arms & Interventions
AER-901 Solution for Nebulization
The inhalation formulation AER-901 for Part A and Part B (Cohort B1 only) is a sterile, yellow solution composed of imatinib mesylate and sterile water for injection. AER-901 will be supplied in 2 solution strengths (5 mg/mL and 40 mg/mL) for nebulisation. The AER-901 inhalation formulation for Part D is a sterile yellow solution composed of imatinib mesylate, sterile water for injection and propylene glycol. AER-901 will be supplied in 2 solution strengths (5 mg/mL and 40 mg/mL) and the Pharmacy Manual will provide guidance on preparation for nebulization. Following review of the Part D safety and PK data by the SRC, the SRC will recommend which formulation and dose of AER-901 (sterile water vs propylene glycol) will be used in Parts B (Cohorts B2 and B3) and Part C. The solution will be filled into a suitable container-closure system and delivered via a nebuliser known as the FOX® MOBILE. The water acts as the medium for nebulisation.
Intervention: AER-901 Solution for Nebulization
Placebo
A volume-matching placebo (0.45% sterile saline for injection) is to be delivered via the FOX® MOBILE device.
Intervention: Placebo
Outcomes
Primary Outcomes
Number of Participants with Treatment Emergent Adverse Events (TEAEs)
Time Frame: From randomization though study completion (up to 17 days following last treatment)
TEAEs will be summarized by treatment group using frequency and percent for each system organ class and preferred term within each system, organ and class (SOC)
Number of Participants with Serious Adverse Events (SAEs)
Time Frame: From randomization though study completion (up to 17 days following last treatment)
SAEs will be summarized by treatment group using frequency and percent for each system organ class and preferred term within each system, organ and class (SOC)
Secondary Outcomes
- Systemic exposure to imatinib (in plasma) after a single administration of AER-901 (Part A)(Pre-dose through 72 hours post dose)
- Systemic exposure to imatinib (in plasma) after multiple administrations of AER-901 (Part B)(Pre-dose through 96 hours post last dose)
- Systemic exposure to imatinib (in urine) after single administration of AER-901 (Part A)(Pre-dose through 72 hours post dose)
- Systemic exposure to imatinib (in urine) after multiple administrations of AER-901 (Part B)(Pre-dose through 96 hours post last dose)